Gemcitabine plus irinotecan in breast cancer patients pretreated with taxanes and anthracyclines: A multicenter phase II study

Oncology

Volumn 64, Issue 4, 2003, Pages 477-478

  Agelaki, S ^a   Karyda, E ^b   Kouroussis, Ch ^a   Ardavanis, A ^c   Kalbakis, K ^a   Malas, K ^b   Malamos, N ^d   Alexopoulos, A ^c   Tselepatiotis, E ^b   Georgoulias, Vassilis ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b South West Hospital of Athens   (Greece)

^c Agios Savvas Cancer Hospital   (Greece)

^d HELENA VENIZELOU HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CAMPTOTHECIN; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADULT; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CARCINOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; LETTER; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; SURVIVAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; AGED; BREAST TUMOR; DRUG ADMINISTRATION; DRUG RESISTANCE; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CAMPTOTHECIN; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0037974858     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000070312     Document Type: Letter

References (11)

1. Blum J, Jones S, Buzdar A, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17:485-493.
2. Possinger K, Kaufmann M, Coleman R, Stuart NS, Helsing M, Ohnmacht U, Arning M: Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. Anticancer Drugs 1999;10:155-162.
3. Blackstein M, Vogel C, Ambinder R, Cowan J, Pearce P, Iglesias J, Dorr FA: Phase II study of gemcitabine in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 1996;15:A135.
4. Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J, Harris AL: Advanced breast cancer: A phase II trial with gemcitabine. J Clin Oncol 1995;13:2731-2736.
5. Spielmann M, Llombart-Cussac A, Kalla S, Espie M, Namer M, Ferrero JM, Dieras V, Fumoleau P, Curvier C, Perrocheau G, Ponzio A, Kayitalire L, Pouillart P: Single agent gemcitabine is active in previously treated metastatic breast cancer. Oncology 2001;60:303-307.
6. Taguchi T, Tominaga T, Ogawa M, Ishida T, Morimoto K, Ogawa N: A late phase II study of CPT-11 (irinotecan) in advanced breast cancer. CPT-11 Study Group on Breast Cancer (in Japanese). Gan To Kagaku Ryoho 1994;21:1017-1024.
7. Bonneterre J, Pion JM, Adenis A, Tubiana-Hullin M, Tursz T, Marty M, Mathieu-Boué A: A phase II study of a new camptothecin analogue CPT-11 in previously treated advanced breast cancer patients. Proc Am Soc Clin Oncol 1993;12:A179.
8. Bahadori HR, Lima CM, Green MR, Safa AR: Synergistic effect of gemcitabine and irinotecan (CPT-11) on breast and small cell lung cancer cell lines. Anticancer Res 1999;19:5423-5428.
9. Smorenburg CH, Bontenbal M, Seynaeve C, van Zuylen C, de Hens G, Verweij J, de Wit R: Phase II study of gemcitabine in patients with metastatic breast cancer failing both an anthracycline and a taxane. Breast Cancer Res Treat 2001;66:83-87.
10. Valerio MR, Cicero MG, Armata E, Bajardi E, Crosta A, Badalamenti G, Arcara C, Agosta G, Vieni S, Latteri F, Russo A, Gulotta G, Gebbia N: Gemcitabine in pretreated breast cancer. Proc Am Soc Clin Oncol 2001;19:A1953.
11. Kakolyris S, Souglakos J, Koukourakis M, Kalbakis K, Mavroudis D, Vardakis N, Georgoulias V: A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy. Anticancer Res 2002;22:1891-1896.